ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2748

Prevalence of Comorbidities in Patients with Axial Spondyloarthritis and Its Association with Aspects of the Disease

Maria Celeste Orozco1, Ana Lizarraga2, Graciela Betancur2, Natalia Zamora1, Fernando Andres Sommerfleck3, Emilce Schneeberger4 and Gustavo Citera4, 1Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Rheumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Comorbidity and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The presence of comorbidities in patients with rheumatic diseases affects functional capacity and quality of life, but also they can limit the therapeutic approach of the disease. Our purpose was to analyze the frequency of comorbidities in patients with Axial Spondyloarthritis (axSpA) and to assess their influence on different aspects of the disease.

Methods: Patients ≥18 years old diagnosed with axSpA (mNY 1987 and/or ASAS 2009 criteria) belonging to ESPAXIA (Estudio de Espondiloartritis Axial IREP Argentina) cohort were included. Demographic data, disease duration, and current treatment were collected. Pain, patient global assessment (VAS), disease activity (BASDAI), functional capacity (BASFI), enthesitis (MASES), axial mobility (BASMI), quality of life (ASQoL) and radiological damage (mSASSS) were assessed. The presence of comorbidities was evaluated and the Charlson comorbidity index was calculated.

Results:  204 patients were included, 74% were male, median age 46 years (IQR 35-57) and median disease duration 19 years (IQR 9-29). Seventy-three patients (35.8%) had at least one comorbidity, being the most common: cardiovascular (40.7%), gastrointestinal (38.7%), endocrine (16.2%), hepatobiliary (11.3%) and respiratory disease (9.3%). Patients with comorbidities were significantly older (56.9±13.6 yrs vs 41.4±12.1 yrs p= 0.0001) and had longer disease duration (26.9±14.4 yrs vs 16.8±11.2 yrs, p= 0.0001). After adjusting for these confounders, patients with comorbidities had worse functional capacity (mean BASFI 4.8± 2.9 vs 3.3± 2.8, p = 0.0001), lower quality of life (mean ASQoL 7.4±5.6 vs 5.8± 5.1, p= 0.02) and higher radiological damage (mean mSASSS 40.4±25.2 vs 20.4±21.7, p = 0.001). In multiple regression analysis, the presence of comorbidities remained significantly associated with worse functional capacity and quality of life. When we divide patients according to the number of comorbidities; 49 (24%) had one comorbidity, 18 (8.8%) two comorbidities and 6 (2.9%) three or more comorbidities, however, the number of comorbidities did not modify our findings. 

Conclusion: 35.8% of patients with axSpA presented comorbidities and that was associated with worse functional capacity, poor quality of life and greater radiographic damage, regardless of the number of comorbidities present.


Disclosure: M. C. Orozco, None; A. Lizarraga, None; G. Betancur, None; N. Zamora, None; F. A. Sommerfleck, None; E. Schneeberger, None; G. Citera, None.

To cite this abstract in AMA style:

Orozco MC, Lizarraga A, Betancur G, Zamora N, Sommerfleck FA, Schneeberger E, Citera G. Prevalence of Comorbidities in Patients with Axial Spondyloarthritis and Its Association with Aspects of the Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-comorbidities-in-patients-with-axial-spondyloarthritis-and-its-association-with-aspects-of-the-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-comorbidities-in-patients-with-axial-spondyloarthritis-and-its-association-with-aspects-of-the-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology